Mitochondrial toxicities of nucleoside reverse transcriptase inhibitors
15 June 2000. Related: Side effects.
2000
HIV drug resistance testing: update
15 June 2000. Related: Guidelines, Drug resistance.
Exercise testing in HIV patients with random increased lactic acid levels: evidence for a reduced anaerobic threshold with a pattern of mitochondrial dysfunction
15 June 2000. Related: Conference reports, Side effects.
Letter: Project Inform nelfinavir potency concerns article
15 June 2000. Related: Correspondence.
Accelerated bone mineral loss in HIV-positive patients receiving potent antiretroviral therapy
15 June 2000. Related: Side effects.
Antiretroviral therapy improves thymic output in some HIV-infected children
15 June 2000. Related: Paediatric care.
Didanosine systemic exposure in children similar with or without food, high interpatient variability suggests TDM to titrate individual dosages
15 June 2000. Related: Antiretrovirals, Paediatric care.
CD8+-cell antiviral factors not restricted to cytotoxic T cells induced during HIV
15 June 2000. Related: Basic science and immunology.
What is Armenicum?
15 June 2000. Related: Other news.
HIV-related anal cancer incidence increased in long-term survivors
15 June 2000. Related: Coinfections and complications.
Irreversible renal dysfunction linked to long-term indinavir therapy
15 June 2000. Related: Side effects.
Drug companies fail to conduct necessary post-marketing studies
15 June 2000. Related: Other news.
Low level HIV replication despite good virological response may explain CD4+ cell decline in a patient receiving combination nucleoside analogue therapy
15 June 2000. Related: Antiretrovirals, Basic science and immunology.
Phase III study of GM-CSF in advanced HIV disease
15 June 2000. Related: Treatment strategies.
Women and HIV: is it really a biological difference?
15 June 2000. Related: Women's health.
Safety warning on amprenavir oral liquid
15 June 2000. Related: Treatment alerts.
Volume 1 Number 3 June 2000 PDF
1 June 2000. Related: PDFs.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
15 May 2000. Related: Conference reports.
Clinical studies of indinavir/ritonavir as salvage therapy
15 May 2000. Related: Conference reports, Drug resistance.
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
15 May 2000. Related: Conference reports, Drug resistance.
First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands
15 May 2000. Related: Conference reports.
TDM: standardisation and quality control
15 May 2000. Related: Conference reports.
TDM in clinical practice
15 May 2000. Related: Conference reports.
ATHENA – Early results from first randomised study of clinical benefits of TDM
15 May 2000. Related: Conference reports.
TDM for individualising dosing – practicality and efficacy for PIs and RTIs
15 May 2000. Related: Conference reports.
TDM and adherence
15 May 2000. Related: Conference reports.
Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir
15 May 2000. Related: Conference reports, PK and drug interactions.
L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation
15 May 2000. Related: Conference reports, Side effects.
ABT-378/r (lopinavir) now available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Enteric coated ddI available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Nelfinavir potency concerns
15 May 2000. Related: Antiretrovirals.
Liquid formulation of efavirenz available for children in the uk on named patient basis
15 May 2000. Related: Paediatric care.
Most reconstituted CD4 cells naive after HAART in children with HIV
15 May 2000. Related: Paediatric care.
GM-CSF beneficial for patients with advanced HIV disease
15 May 2000. Related: Treatment strategies.
Decreased bone mineral density and HIV protease inhibitors
15 May 2000. Related: Side effects.
A view from the lab: interview with Professor Clive Loveday
15 May 2000. Related: Virology, Treatment advocacy, Other news.
EMEA public statement on Viramune (nevirapine): severe and life-threatening cutaneous and hepatic reactions
15 May 2000. Related: Treatment alerts.
Volume 1 Number 2 May 2000 PDF
1 May 2000. Related: PDFs.
Welcome to HIV Treatment Bulletin (incorporating DrFax)
14 April 2000. Related: Editorial.
7th Conference on Retroviruses and Opportunistic Infections (ROI), January 30-February 2 2000, San Francisco
14 April 2000. Related: Conference reports.
Paediatrics: children are not small (or miniature) adults
14 April 2000. Related: Conference reports, Paediatric care.
HIV-positive women, pregnancy and newborns
14 April 2000. Related: Conference reports, Pregnancy, Drug resistance.
Flu-like symptoms of severe acute HIV infection develop after suspension of HAART
14 April 2000. Related: Conference reports.
Non-clade B virus: epidemiology, testing strategies and resistance
14 April 2000. Related: Conference reports, Drug resistance.
Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women
14 April 2000. Related: Guidelines.
French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3
14 April 2000. Related: Treatment strategies.
St John’s Wort: message from Professor A Breckenridge, Chair, Committee on Safety of Medicines.
14 April 2000. Related: Treatment alerts, PK and drug interactions.
Interactions of St John’s Wort (Hypericum perforatum) preparations
14 April 2000. Related: PK and drug interactions.
Important safety information for people taking St John’s Wort preparations
14 April 2000. Related: PK and drug interactions.
French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3
1 April 2000. Related: Other news.
Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women (April 2000)
1 April 2000. Related: Other news.
French Health Authority approves enteric coated ddI
1 April 2000. Related: Other news.
U.S. FDA approves film-coated nelfinavir mesylate (Viracept™)
1 April 2000. Related: Other news.
St John’s Wort
1 April 2000. Related: Other news.
Volume 1 Number 1 April 2000 PDF
1 April 2000. Related: PDFs.